Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens

Objectives

Provide United States Environmental Protection Agency guidance for assessing lifetime cancer risk from exposure to carcinogens during early life, using a mode-of-action framework and giving priority to chemical- and life-stage-specific evidence where it is available. The guidance addresses whether exposures in childhood, including those that may cause childhood cancer or contribute to cancer later in life, produce greater susceptibility than comparable adult exposure.[1][2][3]

• Assess differences in cancer susceptibility across life stages by considering age-related exposure, physiology, behaviour, intake, metabolism, absorption, activity patterns and dose-response relationships.[4]
• Identify susceptible life stages and populations for dose-response assessment, recognising that developmental windows and relevant age groupings can differ according to tumour type and carcinogenic mode of action.[5][6]
• Apply age-dependent adjustment factors to carcinogens with a mutagenic mode of action when chemical-specific data on early-life susceptibility are unavailable.[3][7]
• Use chemical-specific evidence in preference to default factors where epidemiological studies, animal bioassays, toxicokinetic data, toxicodynamic data or mode-of-action evidence can establish age-related differences in potency.[4][7]
• Develop improved methods and evidence for non-mutagenic and hormonally mediated carcinogens, including through research and toxicity-testing protocols incorporating early-life dosing.[3]

The underlying scientific review finds that early-life exposure can produce higher tumour incidence or cancer potency than adult exposure, particularly for mutagenic carcinogens, but the magnitude varies by chemical, exposure pattern, sex, target organ and developmental period.[8][9]Evidence for non-mutagenic carcinogens is more variable and does not support a uniform adjustment across diverse mechanisms.[10][11][12]

The guidance is intended to support scientifically sound risk assessments and regulatory actions while remaining non-binding; alternative approaches may be used where new science, evidence or policy judgement makes them more appropriate.[1]

Implementation

Implement the guidance through case-by-case cancer risk assessment under the Environmental Protection Agency’s Guidelines for Carcinogen Risk Assessment. Begin with a critical evaluation of the evidence, establish or assess the carcinogenic mode of action, quantify relevant life-stage differences in exposure and potency, and calculate lifetime risk by combining risk across exposure periods.[3][4][13]

• Determine whether the mode of action is mutagenic through a weight-of-evidence assessment that incorporates genetic-endpoint testing, metabolic profiles, physicochemical properties, DNA reactivity and structure-activity analyses.[14][15]
• Use linear low-dose extrapolation when the mode of action is mutagenic or cannot be established, generally basing risk estimates on lifetime average daily exposure.[4][16]
• Apply no general age-related adjustment for a demonstrated non-mutagenic mode of action unless sufficient chemical-specific evidence supports one; use mode-of-action modelling or a reference dose or reference concentration approach for nonlinear non-mutagenic carcinogens.[15][16]
• Apply, for mutagenic carcinogens without adequate chemical-specific early-life data, a 10-fold slope-factor adjustment for exposure from birth to under 2 years, a 3-fold adjustment from age 2 to under 16 years, and no adjustment from age 16 onwards.[17][7]
• Calculate total lifetime risk by summing risk across age-specific exposure periods, adjusting for changes in exposure rate, age and dose-response; for less-than-lifetime exposure, time-weight the daily average lifetime dose by exposure duration and apply relevant adjustments only to exposure before age 16.[13][18]
• Use age-specific exposure estimates where available, or apply the relevant age-segment adjustments to lifetime-average exposure information where they are unavailable.[12]

The default adjustment factors derive from comparisons of juvenile and adult cancer potency in animal studies, using weighted geometric means. They are intended for chronic-study cancer slope factors, because environmental exposures and the studies underlying such factors are generally repeated or chronic rather than acute.[8][10][7]The factors may overestimate or underestimate risk for individual chemicals, and available data did not adequately address tumour latency, late-life exposure or more complex dose-response models.[7]

The evidence base combines animal studies, human epidemiological evidence, developmental biology and radiation research. Reviews compare perinatal, postnatal, juvenile, adult, repeated, lifetime and acute exposure scenarios, while accounting for species, strain, sex, target organ, dosing regimen, exposure route, latency and pharmacokinetic differences.[19][20][21]Human chemical-exposure evidence in childhood is limited, whereas radiation evidence, including the Japanese atomic-bomb survivor Life Span Study, provides more substantial information on age-related cancer risk but may not be directly transferable to chemical carcinogenesis.[22][23][24]

The Technical Panel of the Risk Assessment Forum prepared the guidance, and the Environmental Protection Agency may apply it where suitable and appropriate in its cancer risk assessments.[25][1]The Agency envisages collaboration with federal partners to strengthen research and makes supporting data and analyses available through the Risk Assessment Forum website and accompanying spreadsheets.[5]Risk assessments using the guidance are subject to peer review, but no routine implementation timetable, programme budget, formal performance indicators, surveillance system, reporting cycle or broader accountability framework is specified.[1][5]

Monitoring & Evaluation

The guidance is an evidence-based risk-assessment framework rather than a programme monitoring or cancer-surveillance plan. It evaluates whether exposure during early life confers different cancer susceptibility from exposure in adulthood, particularly for carcinogens with a mutagenic mode of action.[1][3]

• Assess life-stage susceptibility using chemical-specific toxicity, human-biology, exposure, toxicokinetic and toxicodynamic evidence where available, rather than relying automatically on general defaults.[5][4][7]
• Determine mode of action through a weight-of-evidence assessment that can include genetic-endpoint testing, metabolic profiles, physicochemical properties, structure-activity analyses and evidence of DNA reactivity.[14][15]
• Compare juvenile and adult cancer potency by estimating juvenile-to-adult potency ratios from tumour-incidence data, exposure age, sex, species, dosing regimen and study design.[19][20][26]
• Interpret a juvenile-to-adult potency ratio above one as evidence of greater susceptibility after early-life exposure in the relevant experiment, while a ratio below one indicates lower susceptibility.[22]
• Summarise uncertainty through posterior distributions, including 2.5th and 97.5th percentiles that serve a similar purpose to 95% confidence limits in other statistical analyses.[26][27]

Quantitative evaluation draws principally on animal studies comparing early postnatal, juvenile, adult, repeated, lifetime and acute exposures, supplemented by human radiation evidence and developmental-biology information.[19][23][28]Studies are selected where comparable groups and sufficient tumour-incidence information permit estimation over time, while evidence from other species is treated as supporting information where direct age comparisons are difficult.[19]

The analytical framework distinguishes repeated or lifetime exposures from acute exposures because their model fitting and interpretation differ.[14]Repeated and lifetime designs are prioritised for potency adjustment because cancer slope factors and environmental exposures generally concern chronic exposure, whereas many acute studies use routes that are not representative of typical environmental human exposure.[10]

Evidence synthesis identifies substantial heterogeneity by chemical, exposure pattern, target organ, sex and developmental window.[8][9]For mutagenic carcinogens, repeated and lifetime exposure studies showed a weighted geometric mean early-life-to-adult susceptibility ratio of 10.4, compared with 1.5 for acute studies.[8][9]Non-mutagenic carcinogens also showed possible increased early-life susceptibility, but findings were less consistent across mechanisms and compounds.[10][11]

The framework recognises important limitations: childhood cancer is rare; unequivocal human evidence linking environmental chemical exposures to childhood cancer is limited; comparative chemical studies are few; and exposure routes, doses, strains, durations and tissue specificity vary across animal experiments.[29][23][8]Maternal exposure, transplacental carcinogenesis and perinatal dosing require separate consideration because offspring dose may be affected by pregnancy, lactation, maternal metabolism and persistent chemicals.[30][11]

For risk assessment, the guidance supports default age-dependent adjustment factors only where a mutagenic mode of action is established and chemical-specific early-life evidence is unavailable.[1][15]The default adjustment is tenfold for exposure before age two years, threefold from age two to under 16 years, and no adjustment from age 16 onwards; chemical- and life-stage-specific data take precedence where they support a more direct assessment.[17][7]

Transparency and scientific review are supported by publication of guidance-related data and analyses through the United States Environmental Protection Agency Risk Assessment Forum website and accompanying spreadsheets.[5]Risk assessments using the guidance are subject to peer review and may use alternative scientifically justified approaches where appropriate.[1]

No routine implementation monitoring system, reporting cycle, population surveillance arrangement, performance-indicator set, evaluation timetable or formal accountability mechanism is specified.[1][3][16]The principal assessment measures are therefore study-level tumour incidence, relative potency ratios, uncertainty intervals, mode-of-action evidence and life-stage-specific exposure and dose-response information.[26][4][31]

Costing & Financing

No quantified costs, budgets, dedicated allocations, funding sources, financing mechanisms, resource-mobilisation plan, funding gap or economic assumption is specified for the guidance or its implementation.[32][1][3]

• Recognise that chronic bioassays incorporating perinatal exposure are described as more complex and costly than standard bioassays, but no monetary value, funding source or budget implication is provided.[33]
• Use existing scientific evidence, published research, United States Environmental Protection Agency analyses, United Nations Scientific Committee on the Effects of Atomic Radiation analyses and supporting datasets as inputs to assessment, without specifying the resources required to maintain or expand these activities.[22][23]
• Note that further research and toxicity-testing protocols including early-life dosing are identified as desirable for improving the evidence base, but the document does not cost these research needs or identify financing arrangements.[3]

The numerical values in the technical material, including adjustment factors, doses, tumour incidences, potency ratios and uncertainty percentiles, are scientific parameters rather than financial amounts and do not constitute cost items.[17][34][27]